[1]周小琳,陈雪贞,李栋方,等.注射用鼠神经生长因子联合利培酮治疗儿童孤独症的 临床疗效分析[J].医学信息,2018,(17):63-65.[doi:10.3969/j.issn.1006-1959.2018.17.019]
 ZHOU Xiao-lin,CHEN Xue-zhen,LI Dong-fang,et al.Clinical Efficacy of Injection of Mouse Nerve Growth Factor Combined with Risperidone in the Treatment of Childhood Autism[J].Medical Information,2018,(17):63-65.[doi:10.3969/j.issn.1006-1959.2018.17.019]
点击复制

注射用鼠神经生长因子联合利培酮治疗儿童孤独症的 临床疗效分析()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2018年17期
页码:
63-65
栏目:
论著
出版日期:
2018-09-01

文章信息/Info

Title:
Clinical Efficacy of Injection of Mouse Nerve Growth Factor Combined with Risperidone in the Treatment of Childhood Autism
文章编号:
1006-1959(2018)17-0063-03
作者:
周小琳陈雪贞李栋方何展文罗向阳
中山大学孙逸仙纪念医院小儿神经专科,广东 广州 510120
Author(s):
ZHOU Xiao-linCHEN Xue-zhenLI Dong-fangHE Zhan-wenLUO Xiang-yang
Department of Pediatric Neurology,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,Guangdong,China
关键词:
注射用鼠神经生长因子利培酮儿童孤独症
Keywords:
Key words:Mouse nerve growth factor for injectionRisperidoneChildhood autism
分类号:
R749.94
DOI:
10.3969/j.issn.1006-1959.2018.17.019
文献标志码:
A
摘要:
目的 探讨注射用鼠神经生长因子联合利培酮治疗儿童孤独症的临床疗效。方法 选取我院小儿神经专科收治的65例儿童孤独症患儿,随机分为两组,对照组31例患儿单用利培酮治疗,治疗组34例患儿予注射用鼠神经生长因子联合利培酮治疗。所有患儿均在治疗前和治疗后3个月进行ABC量表、CARS量表评定,对比两组患儿量表评分情况及临床有效率。结果 治疗后,治疗组ABC量表中感觉能力、交往能力、运动能力、语言能力及自我照顾5项评分均优于对照组(P<0.05);对照组和治疗组CARS量表总分均比治疗前降低(P<0.05),治疗组与对照组相比,CARS量表总分降低更明显(P<0.05)。治疗组临床有效率为94.11%,高于对照组的77.42%,差异具有统计学意义(P<0.05)。结论 注射用鼠神经生长因子联合利培酮较利培酮单药治疗儿童孤独症疗效更佳,不良反应少。
Abstract:
Abstract:Objective To investigate the clinical efficacy of injection of mouse nerve growth factor combined with risperidone in the treatment of childhood autism.Methods A total of 65 children with autism admitted to our hospital were randomly divided into two groups.31 patients in the control group were treated with risperidone alone,34 patients in the treatment group were treated with injection of mouse nerve growth factor combined with risperidone.All children were assessed on the ABC scale and CARS scale before treatment and 3 months after treatment,and the scores and clinical effectiveness of the two groups were compared.Results After treatment,the scores of sensory ability,communication ability,exercise ability,language ability and self-care in the ABC scale of the treatment group were better than those of the control group(P<0.05),the total scores of CARS scales in the control group and the treatment group were lower than those before treatment(P<0.05).Compared with the control group,the total score of the CARS scale was significantly lower in the treatment group(P<0.05).The clinical effective rate was 94.11% in the treatment group,which was higher than 77.42% in the control group,the difference was statistically significant(P<0.05).Conclusion The injection of mouse nerve growth factor combined with risperidone is better than risperidone in the treatment of childhood autism with less adverse reactions.

参考文献/References:

[1]American Psychiatric Association.Diagnostic and Statistical Manual of MentalDisorders[M].5thed.Virginia:American Psychiatric Publishing,2013:55-59. [2]焦云,刘李燕,蔡小凡.利培酮治疗儿童孤独症谱系障碍11例疗效分析[J].海南医学,2013,24(4):565-566. [3]谢琴,黄卓玮,王朔,等.利培酮口服液治疗儿童孤独症32例的疗效及安全性[J].中国新药杂志,2013,22(8):941-944. [4]邹小兵,邓红珠.美国精神疾病诊断分类手册第5版“孤独症谱系障碍诊断标准”解读[J].中国实用儿科杂志,2013,28(8):561-563. [5]肖宇硕,卢金清,蔡佩,等.中西医治疗儿童自闭症的研究概况[J].湖北中医杂志,2014,36(9):80-82. [6]Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators;Centers for Disease Control and Prevention(CDC).Prevalence of autism spectrum disorder among childrenaged 8 years-autism and development disabilitiesmonitoring network,11 sites,United States,2010[J].MMWR Surveill Summ,2014,63(2):1-21. [7]Sun X,Allison C,Matthews FE,et al.Prevalence ofautism in mainland China,Hong Kong and Taiwan:asystematic review and meta-analysis[J].Mol Autism,2013,4(1):7. [8]Rossignol DA,Genuis SJ,Frye RE.Environmental toxicants and autism spectrum disorders:a systematicreview[J].Transl Psychiatry,2014(4):1-23. [9]Anagnostou E,Drmic I,Buchanan JA,et al.Autismspectrum disorder:advances in evidence-based practice[J].Can Med Assoc J,2014,186(7):509-519. [10]于晓辉,宋涛,王真.利培酮在伴有睡眠障碍的孤独症儿童中的应用分析[J].中国现代医生,2015,53(27):34-36.

相似文献/References:

[1]鲁从林,王先丹,杨遂平,等.奥氮平治疗老年痴呆伴精神行为障碍的临床疗效观察[J].医学信息,2018,(01):138.[doi:10.3969/j.issn.1006-1959.2018.01.053]
 LU Cong-lin,WANG Xian-dan,YANG Sui-ping,et al.The Clinical Efficacy of Olanzapine in the Treatment of Alzheimer's Disease with Mental Behavior Disorder[J].Medical Information,2018,(17):138.[doi:10.3969/j.issn.1006-1959.2018.01.053]
[2]蔡 枫,姚雪阳.利培酮与奥氮平治疗酒精所致精神和行为障碍的临床研究[J].医学信息,2018,(03):137.[doi:10.3969/j.issn.1006-1959.2018.03.048]
 CAI Feng,YAO Xue-yang.Clinical Study of Risperidone and Olanzapine in the Treatment of Alcohol-induced Mental and Behavioral Disorders[J].Medical Information,2018,(17):137.[doi:10.3969/j.issn.1006-1959.2018.03.048]
[3]陈功琦,梁道博.利培酮联合舍曲林治疗精神分裂症阴性症状 疗效和安全性的Meta分析[J].医学信息,2018,(10):65.[doi:10.3969/j.issn.1006-1959.2018.10.020]
 CHEN Gong-qi,LIANG Dao-bo.Meta Analysis of Efficacy and Safety of Risperidone Combined with Sertraline in the Treatment of Schizophrenia with Negative Symptoms[J].Medical Information,2018,(17):65.[doi:10.3969/j.issn.1006-1959.2018.10.020]

更新日期/Last Update: 2018-09-01